Lipid Raft Domains: the Probable Place Where Proteins of the Cholinergic System Meet, Accumulate and Communicate

Cecilio J Vidal*

Department of Biochemistry and Molecular Biology-A, University of Murcia, Regional Campus of International Excellence "Mare Nostrum Campus", Murcia Institute for Biosanitary Research (IMIB), Murcia, Spain

*Corresponding Author:
Vidal CJ
Department of Biochemistry and Molecular Biology-A
University of Murcia, Regional Campus of International
Excellence "Mare Nostrum Campus"
Murcia Institute for Biosanitary Research (IMIB)
Murcia, Spain
Tel: +34-868-884774
Fax: +34-868-884147
Email: [email protected]

Received date: November 11, 2016; Accepted date: November 12, 2016; Published date: November 15, 2016

Citation: Vidal CJ (2016) Lipid Raft Domains: the Probable Place Where Proteins of the Cholinergic System Meet, Accumulate and Communicate. J Clin Mol Endocrinol 1:32. doi: 10.21767/2572-5432.100030

Copyright: © 2016 Vidal CJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
Visit for more related articles at Journal of Clinical and Molecular Endocrinology

Letter to Editor

Acetylcholine (ACh), a classical neurotransmitter of the central and peripheral nervous systems, triggers signal transduction events. The availability of ACh in cells and body fluids relais in the actions of choline acetyltranferase (ChAT), the enzyme that makes ACh from acetyl-coenzyme A and choline [1], and the cholinesterases acetyl- (AChE) and butyrylcholinesterase (BChE) [2]. Owing to their high ACh-hydrolyzing capacity, AChE and BChE allow sustain temporal and spatial control of the great variety of down-stream cellular events that follows activation of nicotinic (nAChRs) and muscarinic receptors (mAChRs). Down-regulation of ChAT decreases the level of available ACh, this ACh deficiency being especially intense in Alzheimer´s disease (AD) owing to the progressive loss of cholinergic neurons in the brain areas involved in cognitive functions [3]. The attempts to overcome this deficiency of ACh by prescribing ChE inhibitors (ChE-I) have been unsuccessful. Over 100 million AD patients have been treated with ChE-I since 1986 and, despite clinical stabilization for up to one year in 20% of them an efficient therapy against cognitive troubles has not been found yet, which has prompted clinicians to pursuit new therapeutic approaches [4]. While at the muscular level the deficiency of AChE is causally related with myasthenic disorders [5], AChE down-expression and the subsequent risen level of ACh likely facilitate intense and long lasting cholinergic effects, which may even favour tumour growth [6-9].

ACh occurs in the blood [10] and many types of non-neuronal cells, including epithelial, endothelial and immune cells along with tumour-derived cells, can produce and release ACh [9]. This non-neuronal ACh likely functions like a local signalling molecule, which, acting through autocrine and paracrine routes, may regulate basic cell functions. The amount of ACh which arises from non-neuronal cells can impair cell cycle regulation and the same may take place with nicotine and other exogenous chemicals capable of occupying the site and mimicking the actions elicited by agonists of nAChRs and mAChRs. An excess of available ACh, and the concurrent over-activation of AChRs, may collaborate to malignancy in intestine, lung, liver and kidney [11]. Inactivation or persistent inhibition of AChE (and BChE) by nerve agents, pesticides or some other xenobiotic may also stimulate cell proliferation and tumour growth [12].

While choline transporters, vesicular transporters of ACh and all classes of nAChRs and mAChRs consist of proteins that span the membrane several times, the full range of AChE proteins are devoid of multiple transmembrane regions. This does not mean that the whole range of AChE variants behave as water-soluble proteins. We shall see below that several classes of AChE proteins occur in cells and tissues as amphiphilic (detergentinteracting, lipid-binding) proteins. Thus, while water-soluble (hydrophilic) AChE species occur in the blood serum, saliva and cerebrospinal fluid [13], tissue-specific mixtures of hydrophilic and amphiphilic AChE species occur in the mouse brain [14], muscle [15], nerve [16], thymus [17] and other visceral organs [18].

The 3’-splicing of the AChE pre-mRNA leads to R (readthrough), H (hydrophobic) and T (tailed) mRNAs, along with their corresponding proteins. Before processing at the rough endoplasmic reticulum (RER), AChER, AChEH and AChET proteins exhibit hydrophilic properties, but addition of glycosylphosphatidylinositol (GPI) supplies amphiphilicity to AChEH subunits [19], and linkage of PRiMA (proline-rich membrane-anchor) does so to tetrameric AChET [20]. The variety of AChE proteins is expanded by including the E1e exon in the 5’-end of the mRNA. The E1e-including AChE mRNAs translates into N-terminally extended N-AChER, N-AChEH and NAChET variants [21]. The protection lent by the N-extension prevents the signal peptide from being cleaved off in the RER. As a result, the transmembrane signal peptide allows linkage to membranes of N-AChE proteins, which, later on move and remain at the cell membrane as ecto-proteins [22]. Summarising, current information indicates that AChE mRNAs and proteins have changed along evolution to generate an ample range of monomeric and oligomeric AChE variants made of N-extended N-AChER, N-AChEH and N-AChET and nonextended AChER, AChEH and AChET.

Thus, N-extension, glypiation and PRiMA addition likely represent evolutionary strategies to solve the difficult task of immobilizing in the cell membrane a series of catalytically competent (and/or not competent?) AChE species with hydrophilic faces exposed outwards. As for the membranebound AChE species, although speculative, it is tempting to think that physiological reasons may are behind the choice of GPI or the transmembrane peptide which include PRiMA and the Nextension: the release of AChE in a catalytically competent state by the actions of phospholipases and proteases [23]. Thus, while the release of catalytic AChE may be useful for withdrawing ACh in interstitial fluids, this loss of AChE may form part of the ways needed for achieving ACh homeostasis in body fluids, tissues and cells.

The widely accepted idea of glypiation as a one of the motifs that favour protein targeting to lipid rafts prompted us to test the presence in rafts of GPI-linked AChEH. The observation of glypiated AChE in rafts of mouse muscle and liver [24] lends weight to our proposal and gives sense to the specific splicing that leads to AChEH protein. But if glypiation allowed directing AChE to raft domains, what about PRiMA? The observation of PRiMA-bound AChE in rafts of brain [25] demonstrated that PRiMA linkage was another means of targeting AChE to rafts. As this point, we wondered whether the N-extension was a third manner of directing AChE to rafts. The observation of distinct NAChE proteins in hepatic rafts [24] allowed us substantiate the proposal. Therefore, N-extension, glypiation and PRiMA addition are not only strategies used by AChE variants for membrane linkage, but also the means by which the variants are hosted in membrane patches that possess high levels of sphingolipid and cholesterol. The targeting to rafts of AChE variants explains previous observations regarding the capacity of AChE to interact with diverse protein partners, including prion protein, aurora B kinase, glycogen synthase kinase-3, the death receptor FAS, the membrane integrin receptor and other proteins that temporally or permanently reside in lipid rafts [26]. The capacity of AChE to interact with an ample range of proteins, the fact that several AChE variants localize to rafts, the relevance of cholesterol for activating M3 mAChR in smooth muscle, and the role of caveolae in M2/M3 mAChR-evoked airways constriction [27] place lipid rafts in the cholinergic scenario. In addition, the colocalization of M3 receptors and AChE variants in hepatic rafts [24] indicates that in liver cells at least both AChRs and AChE variants share the same raft domain. This co-existence makes it possible that the surface membrane of ACh-sensitive cells, regardless of their neural and non-neural origin, can be decorated with raft patches holding AChRs, AChE variants and other proteins of the cholinergic system. Each raft with embedded ACh-related proteins may represent the molecular device used by cells to speed-up spatial and temporal control of cholinergic pulses, but further experiments are needed to validate this possibility.

Acknowledgments

CJV wishes to express most enthusiastic gratitude to his collaborators in the lab Dr. Encarnación Muñoz-Delgado, Dr. Francisco Javier Campoy, Dr. Juan Cabezas-Herrera, Dr. María Teresa Moral-Naranjo, Dr. Susana Nieto-Cerón, and Dr. María Fernanda Montenegro. The research group is supported by institutional funds of the University of Murcia.

References

Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Recommended Conferences

  • 12th World congress on Obesity and EndocrinologyJul 17-19, 2017, Melbourne, Australia
  • Endocrinology and Diabetes SummitSeptember 13-14, 2017 Singapore
  • 2nd International Conference on BiochemistrySeptember 28-29, 2017 Dubai, UAE
  • 7th European Diabetes and Endocrinology CongressFeb 12-13, 2018, Munich, Germany
Flyer image
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh